Category Archives: Marketing & Sales
Parkinson’s Disease Pipeline Key Parkinson’s Disease Companies are Roche, Prothena Biosciences, Biohaven Pharmaceuticals, Neuraly Inc., Cerevance, IRLAB, Neuron23, Ventyx Biosciences, Lundbeck, Sanofi, Eli Lilly and Company, and others The Parkinson’s disease therapeutic landscape is undergoing a transformative shift as over … Continue reading
Digital Wound Measurement Devices Market Key Digital Wound Measurement Devices Companies are MolecuLight Inc., Wound Matrix Inc., Kent Imaging Inc., ARANZ Medical Limited, WoundVision LLC., Stryker, eKare Inc., Net, Perceptive Solutions, Inc., BioVisual Technologies LLC, Smith & Nephew, WoundRight Technologies, … Continue reading
BPL-003 Sales Forecast The global neuropsychiatry landscape is undergoing a paradigm shift, and at the center of this transformation is BPL-003, a next-generation intranasal psychedelic therapy poised to redefine the treatment approach for treatment-resistant depression (TRD) and other neuropsychiatric disorders. … Continue reading
Myositis Clinical Trial Key Myositis companies such as Pfizer, Galapagos NV, Fate Therapeutics, Bristol-Myers Squibb, Gilead Sciences, and CRISPR Therapeutics are spearheading innovation with advanced biologics, small molecules, and cell-based therapies designed to improve treatment outcomes and redefine disease management … Continue reading
Traumatic Brain Injury Clinical Trial Key Traumatic Brain Injury Companies are Oragenics, Inc., SHINKEI Therapeutics, Inc., AlzeCure, Algernon Pharmaceutical, Mitochon Pharmaceuticals, Hoth Therapeutics, BioArctic, Tiziana Life Sciences, and others The Traumatic Brain Injury (TBI) therapeutic landscape is undergoing a transformative … Continue reading
Phase 3 EMN24 IsKia Study: Quadruplet Isa-KRd Regimen Significantly Improves MRD Negativity in Newly Diagnosed Multiple Myeloma The EMN24 IsKia results were based on rigorous NGS MRD testing in all patients who achieved at least a very good partial response. … Continue reading
Vanderbilt Health and Evergreen Therapeutics Report Success in Phase 2 ClearMEMory Trial for EG501 The Phase 2 ClearMEMory trial provided robust clinical evidence over a 12-week period. Patients receiving EG501 showed significant improvements in objectively measured cognitive performance scores compared … Continue reading
Lucescu Realty Announces Sale of Peccole Plaza in Las Vegas, NV for $38.6 Million
NEWPORT BEACH, CALIF. – April 22, 2026 – Mark Lucescu, President of LUCESCU REALTY, a market leading investment real estate services firm, announced today the sale of Peccole Plaza in Las Vegas, Nevada for a total consideration of $38.6 Million. … Continue reading
Clash Creation’s 2026 ranking names 7 UK personal branding agencies across price tiers and maps each to the strategic need it actually serves. The UK media management company’s methodology-led review names seven agencies across pricing tiers, defining a new category … Continue reading
Creative XPS Highlights Why More Traffic Alone Is Not the Answer to Sustainable Business Growth
In today’s competitive business environment, many companies believe inconsistent growth can be solved simply by increasing traffic, launching more campaigns, or generating more leads. According to Creative XPS, that assumption often misses the true issue: disconnected systems. While businesses may … Continue reading
